Drug Information

Drug General Information
Drug ID
D0FT4R
Former ID
DNC001333
Drug Name
Sivelestat
Drug Type
Small molecular drug
Indication Discovery agent Phase 4 [521724], [541582]
Structure
Download
2D MOL

3D MOL
Formula
C20H22N2O7S
InChI
InChI=1S/C20H22N2O7S/c1-20(2,3)19(26)29-13-8-10-14(11-9-13)30(27,28)22-16-7-5-4-6-15(16)18(25)21-12-17(23)24/h4-11,22H,12H2,1-3H3,(H,21,25)(H,23,24)
InChIKey
BTGNGJJLZOIYID-UHFFFAOYSA-N
CAS Number
CAS 331731-18-1
PubChem Compound ID
107706
PubChem Substance ID
10234395, 14759000, 17397876, 26758657, 44436677, 50064306, 50998781, 53800789, 57338198, 76715600, 103277098, 103984170, 104379537, 123392712, 125680070, 126682396, 127564958, 134340533, 135065365, 137156953, 137263939, 140115436, 162183567, 163125720, 163688184, 164192385, 164224889, 172821371, 174006339, 178103057, 179149758, 198973808, 204360313, 208264999, 210275598, 210281257, 215775576, 223657139, 226494344, 242501916, 251971107, 252353896, 252356633
Target and Pathway
Target(s) Leukocyte elastase Target Info Inhibitor [537032]
Elastase 1 Target Info Inhibitor [537405]
KEGG Pathway Transcriptional misregulation in cancer
Systemic lupus erythematosus
Pathway Interaction Database Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
C-MYB transcription factor network
Reactome Collagen degradation
Degradation of the extracellular matrix
Activation of Matrix Metalloproteinases
WikiPathways Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
Human Complement System
Degradation of collagen
References
Ref 521724ClinicalTrials.gov (NCT00219375) Study of Sivelestat Sodium Hydrate in Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS) in Japan. U.S. National Institutes of Health.
Ref 541582(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6441).
Ref 537032Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB. Inflamm Res. 2009 Apr;58(4):198-203.
Ref 537405Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both ARDS and DIC patients. Shock. 2009 May 18.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.